BioCurity

BioCurity Pharmaceuticals Inc. operates as a preclinical-stage biopharmaceutical company focused on mitigating the adverse side effects of radiation therapy for cancer patients. Incorporated on February 23, 2015, the company is developing proprietary drugs aimed at preventing radiation-induced damage to healthy tissues without compromising the efficacy of the cancer treatment. The company's scientific origins trace back to a collaboration between its Scientific Co-Founder, Dr. Cheryl Baker, PhD, and researchers at MD Anderson Cancer Center Orlando and the University of Central Florida. This partnership was driven by the need to find a solution for the severe side effects experienced by their cancer patients undergoing radiation. Dr. Baker is listed as the company's Chief Scientific Research Officer.

The core of BioCurity's technology is the use of cerium oxide nanoparticles. These nanoparticles exhibit a dual-action mechanism; in the neutral pH environment of healthy tissue, they act as a powerful antioxidant, breaking down harmful reactive oxygen species generated by radiation. Conversely, in the acidic microenvironment of cancerous tissue, they enhance the production of these damaging molecules, potentially increasing the radiation's effectiveness against the tumor. This selective activity is a key differentiator, aiming to protect the patient's healthy cells while targeting cancer cells. The technology has been studied in preclinical models for a variety of cancers, including breast, lung, head and neck, and pancreatic cancer.

BioCurity is advancing two primary drug formulations based on this nanoparticle technology: a topical cream designed to prevent radiation dermatitis (skin burns, sores, and scarring) and an intravenous (IV) solution intended to protect internal organs and tissues. The company has engaged with the FDA, holding a Pre-IND (Investigational New Drug) meeting in December 2016 to discuss its development plan for the topical drug. The business model is typical for a preclinical biopharmaceutical firm, centered on progressing its drug candidates through the rigorous clinical trial process to eventually secure regulatory approval and commercialize its products. Revenue generation is not expected in the near future, as the company remains in the development phase. To finance its research and development, BioCurity has raised capital through several rounds, including seed funding, venture capital, and equity crowdfunding.

Keywords: preclinical biopharmaceutical, radiation therapy side effects, radiation dermatitis, cerium oxide nanoparticles, supportive cancer care, oncology, drug development, topical radioprotectant, intravenous radioprotectant, reactive oxygen species, cancer treatment toxicity, normal tissue protection, nanomedicine, head and neck cancer, breast cancer, clinical trials, FDA approval, biopharma, life sciences, cancer patient quality of life